Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ) Bundle
A Brief History of Jilin Aodong Pharmaceutical Group Co., Ltd.
Jilin Aodong Pharmaceutical Group Co., Ltd., established in 1998, is based in Jilin Province, China. The company focuses on the research, development, production, and sale of pharmaceuticals and healthcare products. Aodong has made significant investments in technology and R&D, which have propelled it into one of the leading pharmaceutical companies in the region.
In 2000, Aodong was listed on the Shanghai Stock Exchange (stock code: 600538), marking a pivotal moment in its growth trajectory. As of the end of 2022, the company recorded total assets worth approximately 6.92 billion CNY, showing an increase from previous years.
By 2010, Jilin Aodong had expanded its product line, which included traditional Chinese medicine and chemical pharmaceuticals. The company reported a revenue of 2.15 billion CNY with a net profit of 236 million CNY. This period emphasized the company's diversification strategy, allowing it to adapt to changing healthcare demands.
In 2015, Aodong launched a significant marketing campaign aimed at enhancing brand visibility in both domestic and international markets. This campaign contributed to a revenue increase of 20% over the previous year, reflecting the effectiveness of their strategic investments.
For the fiscal year 2021, Jilin Aodong Pharmaceutical achieved a revenue of 3.62 billion CNY, with a net profit margin of 12%. The company saw continued growth in its respiratory system and cardiovascular products, which accounted for over 60% of its total revenue, underscoring its focus on critical healthcare needs.
| Year | Total Assets (CNY) | Revenue (CNY) | Net Profit (CNY) | Net Profit Margin (%) |
|---|---|---|---|---|
| 2010 | 4.15 billion | 2.15 billion | 236 million | 11% |
| 2015 | 5.5 billion | 2.58 billion | 298 million | 11.5% |
| 2021 | 6.3 billion | 3.62 billion | 434 million | 12% |
| 2022 | 6.92 billion | 4.12 billion | 490 million | 11.9% |
As of mid-2023, the company continues to explore international collaborations and innovative drug development initiatives. The recent push towards digital transformation in healthcare has led Aodong to invest in telemedicine and artificial intelligence technologies, further positioning itself to meet modern healthcare challenges.
In addition to its pharmaceutical pursuits, Jilin Aodong has also engaged in corporate social responsibility, focusing on health education and community health programs, reflecting its commitment to corporate citizenship in the pharmaceutical sector.
A Who Owns Jilin Aodong Pharmaceutical Group Co., Ltd.
Jilin Aodong Pharmaceutical Group Co., Ltd. trades on the Shenzhen Stock Exchange under the ticker symbol 002728.SZ. As of the end of 2022, the company reported a market capitalization of approximately ¥16.5 billion (about $2.5 billion USD).
The largest shareholder of Jilin Aodong is the state-owned enterprise, Jilin Aodong Pharmaceutical Group, which holds approximately 34.21% of the total shares. The share distribution is as follows:
| Shareholder | Percentage of Ownership | Number of Shares |
|---|---|---|
| Jilin Aodong Pharmaceutical Group | 34.21% | 143 million |
| Other Institutional Investors | 25.87% | 107 million |
| Public Shareholders | 39.92% | 165 million |
In 2022, Jilin Aodong generated revenue of approximately ¥4.2 billion (around $640 million USD), with a net profit margin of 12.5%. This translates to a net income of roughly ¥525 million (around $80 million USD).
The company's financial health is assessed through its current ratio, which stands at 2.15, indicating a strong liquidity position. Additionally, Jilin Aodong has maintained a stable return on equity (ROE) of approximately 15.2% over the past three fiscal years.
As of the latest shareholder meeting held in March 2023, the executive team remains largely composed of original founders and individuals with significant industry experience, further solidifying control over strategic decisions within the company. The management team consists of a number of notable figures, with the CEO owning around 3.5% of the company’s shares.
Under the current regulatory framework in China, the company is obligated to disclose significant shareholdings and changes in ownership. In the last fiscal year, no major shifts in share ownership have been recorded among the top stakeholders.
Jilin Aodong Pharmaceutical Group Co., Ltd. Mission Statement
Jilin Aodong Pharmaceutical Group Co., Ltd. is a prominent player in China's pharmaceutical industry, focusing on the development, production, and sale of traditional Chinese medicine and Western pharmaceuticals. The company's mission statement reflects its commitment to quality, innovation, and health improvement.
As per the latest available financial data, Jilin Aodong Pharmaceutical reported a revenue of ¥2.79 billion in the fiscal year ended December 31, 2022, marking a year-on-year increase of 8.2%. The net profit for the same period was ¥196 million, reflecting a profit margin of 7.0%.
The company emphasizes a mission centered around several key principles:
- To innovate in drug development and improve the health of the population.
- To adhere to traditional practices while integrating modern scientific methods.
- To expand access to healthcare solutions through efficient distribution channels.
- To foster sustainable practices within its operations.
The operational focus also includes a commitment to R&D investment. In 2022, Jilin Aodong invested ¥150 million in research and development, accounting for approximately 5.4% of total revenue. This investment highlights the company's strategic direction towards enhancing product efficacy and safety through innovative research.
Jilin Aodong’s product portfolio encompasses over 200 varieties of medications, including both traditional Chinese herbal products and chemical drugs. The company also exports its products to over 30 countries, contributing to its international growth strategy.
| Key Financial Metrics | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue (¥ billion) | 2.58 | 2.58 | 2.79 |
| Net Profit (¥ million) | 180 | 189 | 196 |
| R&D Investment (¥ million) | 120 | 135 | 150 |
| Profit Margin (%) | 6.9 | 7.3 | 7.0 |
In addition to its mission, Jilin Aodong is focused on corporate social responsibility, aiming to enhance community health through various initiatives. The company participates in rural healthcare programs and supports public health campaigns which align with its mission to improve the overall health and well-being of the communities it serves.
The company’s dedication to its mission is evident in its sustained market presence and its commitment to manufacturing high-quality products. As of the latest reports, Jilin Aodong holds a market capitalization of approximately ¥5.5 billion and has shown resilience in the face of market challenges, particularly during the COVID-19 pandemic, where it continued to supply essential medications.
In conclusion, Jilin Aodong’s mission statement embodies its core values of innovation, quality, and community health, reflected in its financial performance and operational strategies.
How Jilin Aodong Pharmaceutical Group Co., Ltd. Works
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the research, development, manufacturing, and sale of various medicines, especially traditional Chinese medicine (TCM). The company was founded in 1994 and is based in Jilin City, Jilin Province, China.
The company's product portfolio includes over 100 pharmaceutical products, ranging from prescription medications to over-the-counter drugs. Jilin Aodong emphasizes its commitment to TCM, integrating modern technology into traditional practices to enhance efficacy and safety.
Financial Performance
As of the latest reports, Jilin Aodong's revenue for the year 2022 was approximately 4.6 billion RMB (approximately 670 million USD), showcasing a growth of 12% compared to 2021. The net profit for the same year reported was around 460 million RMB (about 67 million USD), reflecting an increase of 15% year-over-year.
| Year | Revenue (RMB) | Net Profit (RMB) | EPS (RMB) |
|---|---|---|---|
| 2020 | 3.9 billion | 400 million | 0.73 |
| 2021 | 4.1 billion | 400 million | 0.73 |
| 2022 | 4.6 billion | 460 million | 0.84 |
Market Position
Jilin Aodong is a key player in the Chinese pharmaceutical market, particularly in the TCM segment. The company's market share in the TCM sector is estimated at 6%. Its well-established distribution network spans over 30 provinces and municipalities across China.
Research and Development
The firm invests heavily in R&D, allocating approximately 5% of its revenue toward developing new products and enhancing existing ones. In 2022, Jilin Aodong launched 10 new products, mainly focused on respiratory and digestive health.
- Investment in R&D (2022): 230 million RMB
- New Products Launched (2022): 10
Manufacturing Capabilities
Jilin Aodong operates multiple manufacturing facilities, certified by the China Food and Drug Administration (CFDA). The facilities meet international standards, including Good Manufacturing Practices (GMP). The production capacity is estimated at 1 billion units annually.
International Expansion
In recent years, Jilin Aodong has expanded its international footprint, exporting products to more than 20 countries, including the United States, Canada, and several countries in Southeast Asia. The export revenue accounted for approximately 15% of total revenue in 2022, amounting to 690 million RMB.
Environmental and Social Responsibility
The company has also taken steps towards sustainability. In 2022, Jilin Aodong initiated several green practices, reducing its carbon footprint by 12% through energy-efficient technologies in their manufacturing processes.
Through these strategies, Jilin Aodong Pharmaceutical Group Co., Ltd. continues to solidify its position in the pharmaceutical industry, driven by its commitment to R&D, international growth, and sustainable practices.
How Jilin Aodong Pharmaceutical Group Co., Ltd. Makes Money
Jilin Aodong Pharmaceutical Group Co., Ltd. (stock code: 000623) operates mainly within the pharmaceutical industry, focusing on the research, development, manufacturing, and sale of traditional Chinese medicine and modern pharmaceuticals. The company has various revenue streams, with significant portions coming from prescription drugs, over-the-counter medications, and healthcare products.
In 2022, Jilin Aodong reported total revenue of approximately RMB 2.52 billion, a modest increase from RMB 2.39 billion in 2021. This growth can largely be attributed to increased sales of prescription medicines, which accounted for about 70% of total revenue. The company's net profit for 2022 was around RMB 221 million, reflecting a profit margin of roughly 8.8%.
Revenue Breakdown
| Segment | Revenue (RMB) | Percentage of Total Revenue |
|---|---|---|
| Prescription Medications | RMB 1.76 billion | 70% |
| Over-the-Counter Products | RMB 576 million | 23% |
| Healthcare Products | RMB 168 million | 7% |
The company's prescription medications include a variety of traditional Chinese medicines that have gained popularity due to their effectiveness and natural ingredients. Jilin Aodong has invested heavily in research and development, resulting in a robust pipeline of products that cater to various therapeutic areas including anti-cancer, cardiovascular, and neurological treatments.
Market Position and Competitiveness
As of 2023, Jilin Aodong Pharmaceutical holds a market capitalization of approximately RMB 11.4 billion. The company has strategically positioned itself in the Chinese market, which has seen an annual growth rate of about 8% in the pharmaceutical sector. The adoption of advanced technology and innovation, along with a strong distribution network, has enabled Jilin Aodong to enhance its market share.
Moreover, Jilin Aodong's exports have also contributed significantly to its revenue, particularly in Asian markets. In 2022, exports accounted for about 15% of total revenue, amounting to approximately RMB 378 million.
Financial Performance Indicators
| Indicator | 2022 | 2021 |
|---|---|---|
| Total Revenue | RMB 2.52 billion | RMB 2.39 billion |
| Net Profit | RMB 221 million | RMB 208 million |
| Profit Margin | 8.8% | 8.7% |
| Market Capitalization | RMB 11.4 billion | RMB 10.8 billion |
Investment in marketing and brand awareness has also been crucial. Jilin Aodong's branding efforts emphasize traditional Chinese medicine's holistic benefits while balancing modern pharmaceutical advancements. This unique positioning appeals to both domestic and international consumers.
The company continues to explore new avenues for revenue generation, including the development of personalized medicine and expanding its product offerings to include more preventative healthcare solutions, which are increasingly in demand in today's healthcare landscape.
Challenges and Opportunities
Despite its successes, Jilin Aodong faces challenges such as regulatory pressures and intense competition within the pharmaceutical landscape. However, opportunities abound in the growing global demand for health products, particularly amid an aging population and rising health awareness among consumers.
Overall, Jilin Aodong Pharmaceutical Group Co., Ltd. has established a solid foundation for profitability through diverse product lines, strong market positioning, and continuous innovation in the pharmaceutical industry.
Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.